Latest Breaking News On - Blueprint for action national academy of sciences - Page 8 : comparemela.com

(OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).  This is the first step in the registration of Endari® by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait.  The KDFC has accepted Emmaus s request for fast-track review of Endari®, which is expected to take not more than twelve months.  Endari®, Emmaus prescription grade L-glutamine oral powder, is approved by the United States Food and Drug Administration for treating sickle cell disease in adult and pediatric patients five years of age and older.

Saudi arabiaUnited statesYutaka niiharaGeorge sekulichCenters for diseaseCommittee on addressing sickle cell diseaseCompany contactDrug administrationExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesEmmaus life sciencesEmmaus life sciences incDrug authorityLife sciencesFormerly known as emmaus medical